Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery

Reuters

2025/06/23

Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery

XtalPi Holdings Ltd. has announced a new partnership with DoveTree LLC, a company founded by Professor Gregory Verdine. This collaboration involves XtalPi utilizing its end-to-end AI drug discovery platform, which integrates "AI + robotics" technology, to develop small molecule and antibody drug candidates targeting tumors, autoimmune diseases, and neurological conditions. As part of the agreement, XtalPi will receive an initial payment of US$51 million, followed by an additional US$49 million within 180 days post-signing of the Definitive Agreement. The partnership also includes potential milestone and sales payments, reaching billions, and royalties based on a single-digit percentage. This collaboration aims to leverage XtalPi's technological strengths to bring breakthrough therapies to patients globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief on June 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545456098"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545456098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545456098?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 07:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545456098","market":"nz","top_or_hot":-1,"title":"Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XtalPi Holdings Ltd. has announced a new partnership with DoveTree LLC, a company founded by Professor Gregory Verdine. This collaboration involves XtalPi utilizing its end-to-end AI drug discovery platform, which integrates \"AI + robotics\" technology, to develop small molecule and antibody drug candidates targeting tumors, autoimmune diseases, and neurological conditions. As part of the agreement, XtalPi will receive an initial payment of US$51 million, followed by an additional US$49 million within 180 days post-signing of the Definitive Agreement. The partnership also includes potential milestone and sales payments, reaching billions, and royalties based on a single-digit percentage. This collaboration aims to leverage XtalPi's technological strengths to bring breakthrough therapies to patients globally.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-23 07:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XtalPi Holdings Ltd. has announced a new partnership with DoveTree LLC, a company founded by Professor Gregory Verdine. This collaboration involves XtalPi utilizing its end-to-end AI drug discovery platform, which integrates \"AI + robotics\" technology, to develop small molecule and antibody drug candidates targeting tumors, autoimmune diseases, and neurological conditions. As part of the agreement, XtalPi will receive an initial payment of US$51 million, followed by an additional US$49 million within 180 days post-signing of the Definitive Agreement. The partnership also includes potential milestone and sales payments, reaching billions, and royalties based on a single-digit percentage. This collaboration aims to leverage XtalPi's technological strengths to bring breakthrough therapies to patients globally.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nNDL6PJSgZ:1","article_id":"2545456098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545456098","pubTimestamp":1750633605,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"XtalPi Holdings Ltd. has announced a new partnership with DoveTree LLC, a company founded by Professor Gregory Verdine. This collaboration involves XtalPi utilizing its end-to-end AI drug discovery platform, which integrates \"AI + robotics\" technology, to develop small molecule and antibody drug candidates targeting tumors, autoimmune diseases, and neurological conditions. As part of the agreement, XtalPi will receive an initial payment of US$51 million, followed by an additional US$49 million within 180 days post-signing of the Definitive Agreement. The partnership also includes potential milestone and sales payments, reaching billions, and royalties based on a single-digit percentage. This collaboration aims to leverage XtalPi's technological strengths to bring breakthrough therapies to patients globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股","BK1617":"AI医疗","BK1141":"生命科学工具和服务"},"translate_title":"Xtalpi Holdings Ltd.与DoveTree建立人工智能驱动药物发现战略合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":0.9},"content_text":"Xtalpi Holdings Ltd. Enters Strategic Partnership with DoveTree for AI-Driven Drug Discovery\n    \n\n        XtalPi Holdings Ltd. has announced a new partnership with DoveTree LLC, a company founded by Professor Gregory Verdine. This collaboration involves XtalPi utilizing its end-to-end AI drug discovery platform, which integrates \"AI + robotics\" technology, to develop small molecule and antibody drug candidates targeting tumors, autoimmune diseases, and neurological conditions. As part of the agreement, XtalPi will receive an initial payment of US$51 million, followed by an additional US$49 million within 180 days post-signing of the Definitive Agreement. The partnership also includes potential milestone and sales payments, reaching billions, and royalties based on a single-digit percentage. This collaboration aims to leverage XtalPi's technological strengths to bring breakthrough therapies to patients globally.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}